•  
  •  
  •  
  •  

2025-11-28 21:38:13

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Cipla Launches India's First Dedicated Lung Health Diagnostics Center in Delhi
  • Ms. Aditi Nayar, Chief Economist at ICRA Ltd On the Fiscal Deficit
  • Authum Investment & Infrastructure Ltd recommends 4:1 bonus issue
  • SBI Capital Markets Report on Q2FY26 GDP - From Capex to Consumption: How Policy Initiatives Sparked a GDP Beat
  • POSTURA: A Wall-Hung Closet Shaped for Comfort, Crafted for Everyday Life

Keywords Selected:  MarketingAuthorization

Stock Report

  • Cosmo and Glenmark announce Market Authorization of Winlevi® (clascoterone) 10 mg/g cream for Treatment of Acne in 15 countries in Europe
  • Relonchem Limited receives Marketing Authorization for its two products
  • Relonchem Limited receives Marketing Authorization for two of its products
  • Relonchem Limited receives Marketing Authorization for its products
  • Relonchem Limited receives Marketing Authorization for its products
  • Philogen provides update on Marketing Authorization application for Nidlegy™ in the European Union
  • Relonchem Limited receives Marketing Authorization for the product Oxybutynin hydrochloride 2.5mg/5ml Oral Solution
  • Relonchem Ltd receives Marketing Authorization for the product Gabapentin 50 mg/ml oral solution
  • CuraTeQ Biologics received Marketing Authorization for Dyrupeg™, a pegylated filgrastim biosimilar
  • ZIM Laboratories Ltd receives Marketing Authorization for Dimethyl Fumarate (120 mg & 240 mg) Modified Release Capsules in Portugal, Europe
  • Relonchem Limited receives Marketing Authorization for the product Baclofen 10 mg Tablets from UK MHRA
  • Relonchem Ltd receives Marketing Authorization for Ibuprofen and Paracetamol tablets
  • Venus Remedies Secures Marketing Authorization in Philippines
  • Relonchem Limited receives Marketing Authorization from UKMHRA for its products
  • UK Relonchem Ltd, receives Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets
  • ZIM Laboratories Ltd announces grant of Marketing Authorization for Azithromycin for Oral Suspension 200 mg/5ml (40 mg/ml) in Portugal, Europe
  • Submission of Nidlegy™ Marketing Authorization Application Validated by EMA
  • Relonchem Limited receives UKMHRA Marketing Authorization for its products
  • Relonchem Ltd receives Marketing Authorisation for the product Levetiracetam Relonchem 100 mg/mL Oral Solution
  • Shilpa Medicare Ltd receives Europe approval for Amifampridine Tablets, 10 mg
  • CuraTeQ Biologics receives recommendation for grant of marketing authorization of 'biosimilar trastuzumab' from SEC operating under the aegis of CDSCO
  • Venus Remedies Ltd announces successful receipt of new marketing authorization for DOCETAXEL and GEMCITABINE
  • Shilpa Medicare receives UK‐MHRA Approval for Betahistine Dihydrochloride Orodispersible Films, 24 mg
  • Aurobindo Pharma Ltd's subsidiary to withdraw application for EU Marketing Authorization of two biosimilars

Latest Post

  • Cipla Launches India's First Dedicated Lung Health Diagnostics Center in Delhi
  • Ms. Aditi Nayar, Chief Economist at ICRA Ltd On the Fiscal Deficit
  • Authum Investment & Infrastructure Ltd recommends 4:1 bonus issue
  • SBI Capital Markets Report on Q2FY26 GDP - From Capex to Consumption: How Policy Initiatives Sparked a GDP Beat
  • POSTURA: A Wall-Hung Closet Shaped for Comfort, Crafted for Everyday Life


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024